GlassScriptPhysician profile
Marc Dalmond Counts
NPI 1629002043
$3,135.79
in general payments reported to CMS, 2019-2025
26 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $193 · 2021: $357 · 2022: $372 · 2023: $338 · 2024: $643 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $674.53 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $672.46 | 2019-2025 | Lifevest |
| Abbott Laboratories | $391.81 | 2019-2025 | Cardiomems |
| Boston Scientific Corporation | $263.73 | 2019-2025 | Watchman Flx, Eluvia, Bodyguardian |
| Janssen Pharmaceuticals, INC | $197.79 | 2019-2022 | |
| Pfizer INC. | $162.13 | 2019-2024 | |
| Atricure, INC. | $97.79 | 2023-2024 | |
| Daiichi Sankyo INC. | $77.82 | 2021-2024 | Injectafer |
| Irhythm Technologies, INC. | $66.86 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $52.69 | 2020-2025 | Repatha, Repatha |
| Lemaitre Vascular, INC. | $50.76 | 2019 | |
| Heartflow, INC. | $49.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.79 | 2021-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.31 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.21 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $34.63 | 2025 | Optowire |
| Tactile Systems Technology INC | $33.74 | 2025 | Nimbl, Flexitouch Plus |
| Chiesi USA, INC. | $33.08 | 2020-2022 | |
| Lantheus Medical Imaging, INC. | $24.20 | 2024 | |
| Esperion Therapeutics, INC. | $22.54 | 2022 | |
| Scpharmaceuticals INC. | $19.67 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.02 | 2019 | |
| Smith+Nephew, INC. | $18.23 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.00 | 2024 | |
| Novo Nordisk INC | $14.88 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Counts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.